Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

Patent metadata

Field	Value
Publication number	US-10174112-B2
Application number	US-201715623572-A
Country	US
Kind code	B2
Filing date	Jun 15, 2017
Priority date	Feb 20, 2013
Publication date	Jan 8, 2019
Grant date	Jan 8, 2019

Abstract

The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

First claim

We claim:

1. A method of treating an adult T cell leukemia (ATL), comprising administering to an individual suffering from said ATL a therapeutically active amount of an antibody that binds a KIR3DL2 polypeptide and that further: i) directs ADCC toward a KIR3DL2-expressing cell, and/or ii) delivers a cytotoxic agent to a KIR3DL2-expressing cell.

2. The method of claim 1 , wherein the ATL is an HTLV+ ATL.

3. The method of claim 1 , wherein the treatment comprises:
a) determining the KIR3DL2 polypeptide status of malignant cells within the individual having an ATL, and
b) upon a determination that the individual has KIR3DL2 polypeptide expressed on the surface of malignant cells, administering to the individual said antibody that binds a KIR3DL2 polypeptide and that further: i) directs ADCC toward the KIR3DL2-expressing malignant cells and/or ii) delivers a cytotoxic agent to the KIR3DL2-expressing malignant cells.

4. The method of claim 1 , wherein the anti-KIR3DL2 antibody directs ADCC toward a KIR3DL2-expressing cell.

5. The method of claim 4 , wherein the antibody comprises an amino acid modification that enhances binding to a human Fcγ receptor.

6. The method of claim 1 , wherein the antibody is linked to a cytotoxic agent.

7. The method of claim 4 , wherein the anti-KIR3DL2 antibody binds human KIR3DL2 but does not bind to human KIR3DL1.

8. The method of claim 4 , wherein the anti-KIR3DL2 antibody has reduced binding to a KIR3DL2 polypeptide having a mutation at residue P179 and/or residue S181, compared to a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.

9. The method of claim 4 , wherein the anti-KIR3DL2 antibody has reduced binding to a KIR3DL2 polypeptide having a mutation at residue 160 and/or residue G62, compared to a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.

10. The method of claim 1 , wherein the anti-KIR3DL2 antibody binds human KIR3DL2 but does not bind to human KIR3DL1.

11. The method of claim 1 , wherein the anti-KIR3DL2 antibody has reduced binding to a KIR3DL2 polypeptide having a mutation at residue P179 and/or residue S181, compared to a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.

12. The method of claim 1 , wherein the anti-KIR3DL2 antibody has reduced binding to a KIR3DL2 polypeptide having a mutation at residue 160 and/or residue G62, compared to a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.

Assignees

• Innate Pharma

Inventors

• Bonnafous Cecile
• Sicard Helene
• Buffet Renaud

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• G01N33/57505

  of the blood, e.g. leukaemia · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K16/3061

  Blood cells · CPC title